U.S., Aug. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07755345) titled 'Weighted vs Unweighted Plyometric Conditioning on Vertical Jump Performance in Young Male S... Read More
Singapore, Aug. 11 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice of Chemothera... Read More
Singapore, Aug. 11 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, Investigator- and Participant-Blinded, Placebo-Controlled, Randomized, Multiple-Dose St... Read More
U.S., Aug. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07756320) titled 'Precure Targeted Accrual and Rapid Growth in Enrollment Trial Study' on July 28. Brief Sum... Read More
Singapore, Aug. 11 -- The Health Sciences Authority received information related to the study titled 'A Phase 1 randomized, double-blind, placebo-controlled, single-ascending-dose study investigating ... Read More
Singapore, Aug. 11 -- The Health Sciences Authority received information related to the study titled 'A Multinational, Multicenter Study With an Open-Label Phase 1b and a Randomized, Double-Blind, Pla... Read More
Singapore, Aug. 11 -- The Health Sciences Authority received information related to the study titled 'A Global, Multicenter, Prospective, Controlled, Open-Label Pivotal Study of Iodofalan (131I) Solut... Read More
Singapore, Aug. 11 -- The Health Sciences Authority received information related to the study titled 'RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib M... Read More
U.S., Aug. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07754786) titled 'A Study to Evaluate the Equivalence of IBI3027 and Dupilumab Injection in Participants With... Read More
Singapore, Aug. 11 -- The Health Sciences Authority received information related to the study titled 'RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib M... Read More